MCL: first-line VR-CAP delivers deep, durable response vs R-CHOP

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Patients with newly diagnosed mantle cell lymphoma (MCL) achieved deeper, more durable responses with first-line VR-CAP (bortezomib [Revlimid], rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) vs R-CHOP (rituximab [Rituxan] plus cyclophosphamide, vincristine, doxorubicin, and prednisone).

Why this matters

  • In the primary analysis of the LYM-3002 study, VR-CAP delivered 59% improvement vs R-CHOP in median PFS by independent radiology review.  

Study design

  • Analysis of the LYM-3002 phase 3 study to investigate the association between improved outcomes and response associated first-line R-CAP vs R-CHOP in 487 patients with newly diagnosed MCL.
  • 243 patients received VR-CAP, 244 received R-CHOP; 229 and 228 patients, resp...